US regulator orders makers of weight-loss drugs to carry blindness risk warning

Live updates

1. 16m ago

   FDA orders blindness-risk warning for weight-loss drugs Ozempic, Zepbound

   The U.S. Food and Drug Administration has mandated that manufacturers of popular GLP-1 weight-loss and diabetes drugs add a warning about a rare eye condition that can cause sudden vision loss. The label change applies to blockbuster medications including Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Zepbound and Mounjaro. The condition, non-arteritic anterior ischemic optic neuropathy (NAION), reduces blood flow to the optic nerve and can result in permanent blindness. The FDA determined the risk warrants a warning after reviewing adverse event reports, though the agency maintains the drugs' benefits outweigh risks for approved patients.

   Why it matters

   GLP-1 receptor agonists have become widely prescribed for type 2 diabetes and obesity, generating billions in revenue for Novo Nordisk and Eli Lilly. NAION is a rare condition with no proven treatment that causes sudden, painless vision loss in one eye. The FDA's decision follows mounting case reports and a 2024 observational study suggesting a potential association, though causality has not been definitively established. Regulators in Europe and Canada are also reviewing similar safety signals.

   What is confirmed

   • FDA ordered manufacturers to add a warning about non-arteritic anterior ischemic optic neuropathy (NAION) to GLP-1 drug labels.
   • The warning applies to Ozempic, Wegovy, Zepbound, and Mounjaro.
   • NAION is a rare condition causing sudden vision loss due to reduced blood flow to the optic nerve.
   • FDA reviewed adverse event reports before requiring the label change.
   • The agency states the drugs' benefits continue to outweigh risks for approved uses.

   Still unconfirmed

   • A 2024 observational study found an increased NAION risk among semaglutide users compared to non-users.

   What to watch next

   • European Medicines Agency and Health Canada safety reviews on GLP-1s and NAION
   • Potential litigation from patients who experienced vision loss while on these drugs
   • Long-term epidemiological studies to clarify causality versus association
   Sources used for this update (6)

   1. www.thenationalnews.com — Arab Israelis wake to new political dawn after record election success
   2. Financial Times — US regulator orders makers of weight-loss drugs to carry blindness risk warning
   3. CNN — US FDA orders new eye risk warnings for Ozempic, Zepbound
   4. Quartz — FDA is requiring weight loss drug makers to add a vision loss warning
   5. NBC News — FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
   6. The Seattle Times — FDA adds warning label to obesity drugs for eye condition
   confidence 93%